CORD-19:ee0a7632371a08727d41e55aad7d621daeceef7d / 923805-923958 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/ee0a7632371a08727d41e55aad7d621daeceef7d","sourcedb":"CORD-19","sourceid":"ee0a7632371a08727d41e55aad7d621daeceef7d","text":"This panel will greatly benefit patients whose tumors carry low-level actionable mutations and those who require monitoring for minimal residual disease.","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"T6512","span":{"begin":0,"end":153},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T6512","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T433","span":{"begin":0,"end":153},"obj":"Sentence"}],"attributes":[{"subj":"T433","pred":"source","obj":"CORD-19_Custom_license_subset"}]},{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T3892","span":{"begin":47,"end":53},"obj":"Disease"},{"id":"T54462","span":{"begin":47,"end":53},"obj":"Disease"}],"attributes":[{"id":"A3892","pred":"mondo_id","subj":"T3892","obj":"http://purl.obolibrary.org/obo/MONDO_0005070"},{"id":"A72851","pred":"mondo_id","subj":"T54462","obj":"http://purl.obolibrary.org/obo/MONDO_0005070"},{"subj":"T3892","pred":"source","obj":"CORD-19-PD-MONDO"},{"subj":"T54462","pred":"source","obj":"CORD-19-PD-MONDO"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#9cec93","default":true},{"id":"CORD-19_Custom_license_subset","color":"#ec93b6"},{"id":"CORD-19-PD-MONDO","color":"#93d0ec"}]}]}}